

Mr. Carlos Manuel Buesa Arjol

A founder of the Company in 2000, he has held the position of Chair of the Board of Directors since then. He earned his Ph.D. in Biochemistry from the University of Barcelona, and has completed various programs on finance and negotiation. He also completed the Senior Management Program (PADE) at IESE in 2005. In recent years, he has been a member of the board of several biotechnology companies, such as: ONCNOSIS PHARMA AIE, NINFAS AIE, ORYCAMB-PROJECT AIE, GEADIG-PHARMA AIE, NEUROTEC PHARMA, S.L., PALOBIOFARMA, S.L. He has been a member of the Advisory Board of NEUROSCIENCES TECHNOLOGIES and is a member of MENDELION, S.L. He is ORYZON's representative on the Governing Board of the Asociación Española de Bioempresas (ASEBIO), of which ORYZON has been a member since 2005, except for the period between 2009 and 2011, during which ORYZON was appointed as Vice Chair of such Governing Board. The first Vice Chairmanship of ASEBIO is held by Oryzon since the last elections held in December 2017. Finally, he has been a member of the Board of Directors of INVEREADY SEED CAPITAL and of INVEREADY BIOTECH since September 7, 2008 and October 10, 2012, respectively.

Ms. Tamara Maes

A founder of the Company in 2000, she is the Scientific Director, a member of the Board of Directors since its foundation, and the First Vice Chair. She received her PhD. in Biotechnology (genetics) from the University of Ghent (Belgium). She is also a director of MENDELION LIFESCIENCES, S.A., she was a member of the Scientific Advisory Board of the Consejo Superior de Investigaciones Científicas (CSIC) since January 20, 2009, through January 22, 2013, is a member of the Scientific Review Board of the Alzheimer's Drug Discovery Foundation since 2016 and has collaborated with CAIXA CAPITAL RISC in its mentoring program for new entrepreneurs since September 1, 2015.

Mr. José María Echarri Torres

B.Sc. in Economics, Actuarial Sciences, and Financial Sciences from the University of Barcelona, and M.B.A. and M.Sc. in Financial Management from ESADE Business School, he acted as the Chief Financial Officer of ORYZON from 2003 to 2007, prior to which he was responsible for the first integral business technology company creation program developed by a Spanish government. Currently, he is the Chief Executive Officer of INVEREADY ASSET MANAGEMENT, S.G.E.C.R., S.A. and President of the Inveready Financial Group, companies of which he has been the founding member and of which he is currently the largest shareholder. He is a member of the Board of Directors of more than 30 technology companies, such as MASMÓVIL IBERCOM, S.A. (a company listed on the Continuous Market of which he is the Vice President), AGILE CONTENTS, S.L. (company listed on the Alternative Equity Market), ORYZON GENOMICS, S.A. (company listed on the Continuous Market), ATRYS HEALTH, S.A. (company listed on the Alternative Equity Market), AB - BIOTICS, S.A. (company listed on the Alternative Equity Market of which he is an independent director and member of the Audit Committee), PALOBIOFARMA, S.L. or FERSA ENERGÍAS RENOVABLES, S.A. (company listed on the Continuous Market); being an independent director and Chairman of the Audit Committee of the latter.

Mr. Antonio Fornieles Melero (Independent Director and Lead Director, if applicable)

He received a B.S in Economics and Business Studies from the Complutense University of Madrid (1981) and a Diploma in Senior Management in Business Management from the Instituto Internacional San Telmo (Seville) (2002).

He passed the examination to become an auditor in 1987, becoming a member of the ICJCE.

He has more than thirty (30) years of experience in the auditing profession, beginning in 1983, almost of all of which were at KPMG Auditores S.L. (partner since 1994), where he has held the highest professional and management responsibilities, both national and international.

Since April 2017, he has also been the President of the Register of Accounting Experts (*Registro de Expertos Contables*), an entity formed by the ICJCE and the Colegio de Economistas de España to give prestige to the accounting profession.

He has been the President of the 1st territorial grouping (Madrid and Castille-La Mancha) of the ICJCE for eight (8) years. He has also been a member of the Full Board and of the Permanent Commission of the national ICJCE.

He was a member of the Board of Directors of Abengoa from January 2015 to November 2016, on which he first held the positions of Lead Independent Director and Second Vice Chairman and Chairman of the Audit Committee. In March 2016, he was appointed Chairman of Abengoa, a position that he held until November 2016. During this period, he led the efforts to arrive at an agreement on restructuring the company with new investors and financial creditors granting the company's viability.

He has been a lecturer in the faculty of economics and business studies at the University of Cádiz. He is a regular speaker and lecturer at universities, professional corporations and businesses about issues related to financial reporting, business management and corporate governance and ethics. He has also published numerous articles in specialized media.

Mr. Ramón Adell Ramón (Independent Director and Chair of the Audit and Compliance Committee)

Bachelor's degree and PhD. in Economics and Business Administration from the University of Barcelona. B.A. in Law from the University of Barcelona. Certified Public Accountant by the Instituto de Censores de Cuentas de España and Financial Analyst. Full Professor of Financial Economics and Accounting with the Business Department of the University of Barcelona. He has held management positions at various companies throughout his professional career, being part of the team that led the creation and development of the Futures and Options Markets in Spain. He has published various books and numerous articles related to business economics and executive management.

He has been a member of the Board of Directors of Gas Natural SDG, S.A. since June 2010 and Chair of that company's Audit Committee since November 2014. He is a member of the Advisory Board of Planeta Formación y Universidades.

At the institutional level, he has been President of the Societat d'Estudis Econòmics since 2011, Honorary Chairman of the Spanish Association of Managers (*Asociación Española de Directivos*) (AED) since 2010, Vice Chairman of Foment del Treball Nacional since 2014, of the CEDE since 1997, and of Fundació CEDE since 2005, as well as advisory member of the Plenum of the Cambra de Comerç de Barcelona since 2009 and member of the Governing Board of the Institute for Economic Studies (*Instituto de Estudios Económicos*). He is also an Honorary Member of the European Higher Council of Doctors and Doctors Honoris Causa

He has been a fellow of the Spanish Royal Academy of Economic and Financial Sciences since 2016.

Ms. Isabel Aguilera Navarro (Independent Director and Chair of the Appointments and Compensation Committee)

She holds two University degrees in Architecture (Civil Engineering) and Urban Planning from the Escuela Técnica Superior de Arquitectura of Sevilla. She has completed a master program in Commercial and Marketing Management from Instituto de Empresa and the General Management Program from IESE. She also completed the Program for Senior Management of Leading Companies at Instituto San Telmo (Seville).

She is currently an Independent Board Director at LAR España Real Estate SOCIMI, S.A. y de Egasa Siglo XXI. She is a member at the Advisory Boards of Oracle Iberia and Deusto Business School. She is an international speaker at Thinking Heads and she is an associate professor at ESADE.

She has been an independent Board member at: INDRA, BMN (Banco Marenstrum), Aegón España, Board of Directors of Emergia Contact Center and Laureate INC and also was a member at the Advisory Boards of Farmaindustria, Pelayo Mutua de Seguros, Oracle Iberia and Ikor, and for the Board of the Association for the Progress of Management (APD) as well as for the International Advisory Board of Instituto de Empresa (IE Business School) and the Chairman of the Social Board of the University of Seville.

She was a co-founder, shareholder and president of Twindocs Internacional, and founder of Isabel Aguilera Business Consulting on Strategy, Operations and Innovation.

She is the author of two books: “La Encrucijada de Carlota” (“*Carlota at the Crossroads*”, Espasa, 2011) and “Lo que estaba por llegar, ya está aquí” (“*What was coming, is already here*”), La Esfera de los Libros, 2016).

Formerly, she was the President for Spain and Portugal of General Electric in 2008 and 2009. Chief Operating Officer for Spain and Portugal at GOOGLE INC., Chief Operating Officer of NH Hoteles Group and CEO for Spain, Italy and Portugal for DELL Computer Corporation. She has also worked for Airtel Móvil (nowadays VODAFONE) and Hewlett-Packard-Compaq, holding diverse responsibilities in sales and marketing.

Mr. José Carlos Gutiérrez – Ramos (Independent Director)

Dr. José Carlos Gutiérrez-Ramos is a reputed Immunologist. He got his PhD in 1987 at the Center for Molecular Biology - Universidad Complutense de Madrid (Spain). He continued his postdoctoral research first at the Max-Planck Institute für Immunbiologie in Freiburg (Germany) and later as Scientist and Member at the Basel Institute for Immunology of F. Hoffmann-LaRoche in Basel (Switzerland). He is Full Professor (on leave) at the Spanish Scientific Research Council (CSIC) of the National Center for Biotechnology (CNB) in Madrid (Spain). From 1991-97 he was Assistant Professor (tenure track) at the Department of Genetics and Investigator at the Center for Blood Research from Harvard Medical School in Boston (Ma, USA). From 2012 to 2014 he was Lecturer at MIT Sloan School of Management at the MIT Center for Entrepreneurship in Cambridge (Ma, USA).

From his ample experience in the biopharmaceutical industry it is worth noting that in the period 2010-2015, he was Group Senior Vice President WorldWide R&D and Global Head of Biotherapeutics R&D at Pfizer and Head of its Research Center in Cambridge/Boston. Previously from 2007 to 2009 he was Senior Vice President and Director of the Group of Immunoinflammation and Discovery of Drugs (iiCEDD) of GSK, where he founded the Epinova Epigenetics Unit. Previously, he held responsibility functions in Amgen, Peptimmune and Millenium Pharmaceuticals. In his current role as President and CEO of Synlogic (SYBX, NASDAQ) since 2015, he has raised more than two hundred (200) million dollars with the participation of specialized investment funds such as Orbimed, Deerfield, Sofinova, NEA, Atlas, EcoR1, Millenium, Farallon, Perceptive, and RockSprings, among others.